gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 16 Apr 2015.

Apolipoprotein Ea

apolipoprotein E
Top mentioned proteins: apolipoprotein E, AGE, HAD, CAN, V1a
Papers on apolipoprotein E
The role of apolipoprotein E polymorphism in improving dyslipidemia in obese adolescents following physical exercise and National Cholesterol Education Program Step II intervention.
New
Setiawati et al., In J Pediatr Endocrinol Metab, 14 May 2015
Apolipoprotein E (apo E) genotypes and blood lipid levels were compared before and after interventions.
Hypercholesterolemia and ApoE deficiency result in severe infection with Lyme disease and relapsing-fever Borrelia.
New
Benach et al., Stony Brook, United States. In Proc Natl Acad Sci U S A, 13 May 2015
To determine whether higher levels of serum cholesterol could enhance the organ burdens of B. burgdorferi and the spirochetemia of B. hispanica in laboratory mice, apolipoprotein E (apoE)-deficient and low-density lipoprotein receptor (LDLR)-deficient mice that produce large amounts of serum cholesterol were infected with both spirochetes.
The role of APOE-ɛ4 and beta amyloid in the differential rate of recovery from ECT: a review.
Review
New
Martins et al., Australia. In Transl Psychiatry, Dec 2014
A narrative review of the research literature on carriage of the apolipoprotein E ɛ4 allele (APOE-ɛ4) and the protein biomarker beta amyloid (Aβ) with ECT cognitive outcome was undertaken.
Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment.
Review
New
Leng et al., Dalian, China. In Clin Interv Aging, Dec 2014
It is worth mentioning that the therapeutic effects of these drugs are influenced by the apolipoprotein E (APOE)-ε4 genotype.
HDL biogenesis, remodeling, and catabolism.
Review
New
Chroni et al., Boston, United States. In Handb Exp Pharmacol, Dec 2014
Similarly to apoA-I, apolipoprotein E and apolipoprotein A-IV were shown to form discrete HDL particles containing these apolipoproteins which may have important but still unexplored functions.
[The low content of apolipoprotein E as a risk factor of increasing of ratio apolipoprotein B/A-1 in healthy males with normal lipemia].
New
In Klin Lab Diagn, Dec 2014
The relationship of ratio of apolipoprotein (apo) B/apoA-1 with other indicators of lipid metabolism in healthy people with normal lipemia was analyzed.
APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice.
New
Chen et al., In Mol Neurodegener, Dec 2014
One proposed mechanism for apolipoprotein E (apoE) effects on cognition is via NMDAR-dependent signaling.
Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice.
New
Bu et al., In Mol Neurodegener, Dec 2014
BACKGROUND: Human apolipoprotein E (apoE) exists in three major isoforms: apoE2, apoE3 and apoE4.
Cholesterol and metal ions in Alzheimer's disease.
New
Impact
Lim et al., Ann Arbor, United States. In Chem Soc Rev, Nov 2014
For example, (a) cholesterol has been shown to be misregulated in AD-afflicted brains, and the aberrant activity of proteins (particularly, apolipoprotein E (ApoE) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGR)) has been linked to cholesterol-related AD exacerbation; (b) dyshomeostasis of metal ions associated with misfolded proteins (i.e., amyloid-β (Aβ) aggregates) found in the brains of AD patients is shown to promote oxidative stress leading to the malfunction of multiple proteins, including cytochrome c oxidase (CcO), and Cu/Zn superoxide dismutase (SOD1); (c) metal ion misregulation has also been observed to disrupt the activity of proteins (e.g., HMGR, low-density lipoproteins (LDL)), required for cholesterol production and regulation.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
New
Impact
Bapineuzumab 301 and 302 Clinical Trial Investigators et al., Jarash, Jordan. In N Engl J Med, Feb 2014
METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers.
Apolipoprotein E in Alzheimer's disease: an update.
Review
Impact
Hardy et al., Qingdao, China. In Annu Rev Neurosci, 2013
Apolipoprotein E (APOE) has been irrefutably recognized as the major genetic risk factor, with semidominant inheritance, for LOAD.
[Clinical and prognostic significance of genetic markers in craniocerebral injury (Part III)].
Review
Potapov et al., In Vopr Neirokhir, 2013
The first part of the review by Potapov et al. (201 0) [2] was devoted to the role of apolipoprotein E (apoE) gene polymorphism in CCI, the second one [3]- to the role of inflammation and immune response genes in the course and outcome of CCI.
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.
Impact
Amouyel et al., In Nat Genet, 2013
In addition to the APOE locus (encoding apolipoprotein E), 19 loci reached genome-wide significance (P < 5 × 10(-8)) in the combined stage 1 and stage 2 analysis, of which 11 are newly associated with Alzheimer's disease.
Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease.
Impact
Abeliovich et al., New York City, United States. In Nature, 2013
Late-onset Alzheimer's disease (LOAD) risk is strongly influenced by genetic factors such as the presence of the apolipoprotein E ε4 allele (referred to here as APOE4), as well as non-genetic determinants including ageing.
Review
Lau et al., Rockville, United States. In Unknown Journal, 0001
OBJECTIVE: We assessed four pharmacogenetic tests: 1) cytochrome P450, subfamily IIC, polypeptide 9 (CYP2C9), 2) vitamin K epoxide reductase subunit protein 1 (VKORC1), 3) apolipoprotein E (Apo E), and 4) methylenetetrahydrofolate reductase (MTHFR) for their associations with patient’s response to therapy with warfarin (CYP2C9 and VKORC1), statins (Apo E), or antifolate chemotherapy (MTHFR).
share on facebooktweetadd +1mail to friends